SCHEMBL61256

SCHEMBL61256

[CH2]CCCCCCCC#CCCCCCCCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.50
HMGCR P04035 3/20 0.50
RECQL P46063 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
TSHR P16473 1/20 0.42
THRB P10828 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
MCL1 Q07820 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
EPHX2 P34913 3/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3859291 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL3868197 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL3863209 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL313504 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL1475879 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9209758 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL3989043 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9681594 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL8669383 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL3856545 1.00 PTPN7 (0.50) PTPN7HMGCRRECQLTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390378-B1 PHARMACEUTICALLY ACTIVE URIDINE ESTERS TROMMSDORFF ARZNEIMITTEL (DE) 2009-06-17 EP claimed
US-7396826-B2 Pharmaceutically active uridine esters TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) 2008-07-08 US claimed
JP-2004531543-A 2004-10-14 JP claimed
US-20040121979-A1 Pharmaceutically active uridine esters TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) 2004-06-24 US claimed
EP-1390378-A1 PHARMACEUTICALLY ACTIVE URIDINE ESTERS Trommsdorff GmbH & Co. KG Arzneimittel (DE) 2004-02-25 EP claimed
WO-2002088159-A1 PHARMACEUTICALLY ACTIVE URIDINE ESTERS TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) 2002-11-07 WO claimed
EP-0282127-B1 Beta-aminoethyl-substituted phenyl compounds, and anti-inflammatory or analgesic compositions containing them PROCTER & GAMBLE (US) 1994-02-02 EP claimed
US-5045565-A Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain THE PROCTER & GAMBLE COMPANY (US) 1991-09-03 US claimed
EP-0282127-A2 Beta-aminoethyl-substituted phenyl compounds, and anti-inflammatory or analgesic compositions containing them THE PROCTER & GAMBLE COMPANY (US) 1988-09-14 EP claimed
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS, LLC 2023-07-13 US disclosed
US-11612608-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2023-03-28 US disclosed
EP-2871178-B1 CATIONIC LIPID KYOWA KIRIN CO LTD (JP) 2020-12-23 EP disclosed
US-20200368173-A1 NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE KYOWA KIRIN CO., LTD. (JP) 2020-11-26 US disclosed
EP-3162794-B1 ALKYL SUBSTITUTED AZETIDINES AS CATIONIC LIPID KYOWA KIRIN CO LTD (JP) 2020-09-16 EP disclosed
EP-0282127-A2 Beta-aminoethyl-substituted phenyl compounds, and anti-inflammatory or analgesic compositions containing them THE PROCTER & GAMBLE COMPANY (US) 1988-09-14 EP disclosed
US-4649203-A ANTITUMOR, FUNGICIDES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1987-03-10 US disclosed
US-4562005-A ANTITUMOR TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1985-12-31 US disclosed
EP-0138559-A2 Ketoalkylphospholipids and their production and use Takeda Chemical Industries, Ltd. (JP) 1985-04-24 EP disclosed
EP-0108565-A2 Phospholipids, their production and use thereof Takeda Chemical Industries, Ltd. (JP) 1984-05-16 EP disclosed
US-4008258-A MITICIDE ZOECON CORPORATION (US) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121979-A1 Pharmaceutically active uridine esters UMPS, UGDH, FFAR1 PTPN7 4353/4885HMGCR 416/4885RECQL 739/4885
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO PTPN7 4002/4885HMGCR 1124/4885RECQL 96/4885
US-11612608-B2 Methods of treating oral mucositis LPO, SOD3, MPO PTPN7 4002/4885HMGCR 1124/4885RECQL 96/4885
US-20200368173-A1 NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE LIPA, LIPC, PNLIP PTPN7 3186/4885HMGCR 530/4885RECQL 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.